Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL-SR vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/m L.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Adults: 8-10 hours (range 3-12); Neonates: 20-30 hours; Smokers: 4-5 hours; Cirrhosis: 30-40 hours. Dose adjustments needed based on half-life variations.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Hepatic via CYP1A2, CYP2E1, and CYP3A4; demethylation and oxidation to inactive metabolites (1-methyluric acid, 3-methylxanthine, 1,3-dimethyluric acid).
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal: ~10% unchanged; Hepatic metabolism (90%) via CYP1A2, 3A4; metabolites (caffeine, 3-methylxanthine) excreted renally. Total clearance predominantly hepatic.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
40-60% primarily to albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg (1.0-1.5 L/kg in neonates). Reflects distribution into total body water; higher in dehydrated states.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral immediate-release: 96-100%; Sustained-release: 90-100% (variable among formulations).
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No specific GFR-based adjustment required, but serum concentrations should be monitored due to altered clearance. For GFR <10 m L/min, reduce dose by 50% and monitor levels.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B: reduce dose by 60%; Child-Pugh Class C: reduce dose by 80% and monitor serum concentrations closely.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Initial dose: 5 mg/kg/day orally in 2 divided doses, increasing by 2 mg/kg/day every 3 days to maximum 20 mg/kg/day, with monitoring of serum concentrations.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at lower end of dosing range (e.g., 200 mg every 12 hours) and titrate slowly due to reduced hepatic clearance; monitor serum concentrations and adjust to therapeutic trough of 5-15 mcg/m L.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning.
None.
Use with caution in patients with cardiac disease (e.g., arrhythmias), seizure disorders, peptic ulcer disease, hepatic impairment, and in elderly patients. Monitor serum theophylline levels to avoid toxicity.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation; active peptic ulcer disease; seizure disorder (unless appropriately controlled with anticonvulsants).
Hypersensitivity to theophylline or any component of the formulation.
Avoid large amounts of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase adverse effects. Charcoal-broiled foods can increase clearance, potentially decreasing effectiveness. High-carbohydrate/low-protein diets may increase theophylline levels. St. John's wort may decrease theophylline levels.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
FDA Pregnancy Category C. First trimester: No increased risk of major malformations reported in humans; animal studies show fetal harm at high doses. Second trimester: Potential for maternal tachycardia and uterine relaxation, not teratogenic. Third trimester: Risk of neonatal apnea, bradycardia, and jitteriness at birth if maternal levels are supratherapeutic; no structural anomalies.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Excreted into breast milk; M/P ratio approximately 0.6-0.7. Infant dose ~1-10% of maternal weight-adjusted dose; monitor infant for irritability or insomnia. AAP considers compatible with breastfeeding with caution.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Increased clearance and volume of distribution in pregnancy; dose may need to be increased by 20-30% in second and third trimesters. Monitor levels and adjust based on clinical response and trough concentrations.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Theophylline has a narrow therapeutic index (10-20 mcg/m L). Monitor levels due to significant interindividual pharmacokinetic variability. Smoking induces metabolism; dose adjustments needed when starting/stopping smoking. Avoid in tachyarrhythmias, seizure disorders, or peptic ulcer disease. Cimetidine, ciprofloxacin, and erythromycin increase theophylline levels. Convert between immediate-release and sustained-release formulations cautiously. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not crush or chew sustained-release tablets.,Do not change brands or formulations without consulting your doctor.,Avoid large amounts of caffeine (coffee, tea, cola) as it may increase side effects.,Report symptoms of toxicity: persistent nausea/vomiting, insomnia, tremors, seizures, or rapid/irregular heartbeat.,If you smoke, inform your doctor, as dose adjustments may be needed.,Keep all appointments for blood level monitoring.,Do not stop abruptly; may cause rebound bronchospasm.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL-SR vs AEROLATE JR, answered by our medical review team.
THEOPHYL-SR is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL-SR and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL-SR is: 300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/m L.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL-SR and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL-SR is classified as Category C. FDA Pregnancy Category C. First trimester: No increased risk of major malformations reported in humans; animal studies show fetal harm at high doses. Second trimester: Potential fo. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.